CZL80
Based on 1 Customer Validation
CZL80, a brain-penetrable caspase-1 inhibitor with an IC50 of 0.01 μM, could be used in the study of febrile seizures and later enhanced epileptogenic susceptibility.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.31%
- CAS No.: 313482-91-6
- Formule: C19H14N2O4S
- Masse moléculaire:366.39
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Pyroptosis Compound Library
HY-L059
-
Protease Inhibitor Library
HY-L147
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Voir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
|
Caspase-1 0.01 μM (IC50) |
CZL80 delayed-administration is a competent to attenuate the progressive neurological dysfunction induced by photothrombosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice and Caspase-1 gene knockout (Caspase-1−/−) mice weighing 23-26 g (9-10 weeks old)[2].
-
Dosage:10, 30 mg/kg/d, 7 days.
-
Administration:i.p.
-
Result:Rescued motor dysfunction after photothrombotic stroke in mice.
-
Animal Model:Mice pups of caspase-1 knockout (Casp1−/−, RRID:IMSR_JAX:004947) and littermate controls (wild-type [WT], Casp1+/+)[1].
-
Dosage:0.0075, 0.075, 0.75 and 7.5 mg/kg (2% DMSO in saline), qod (every other day).
-
Administration:Intravenously injected.
-
Result:Reduced seizure incidence, prolonged seizure latency and increased threshold to FS generation in a dose-dependent manner.
Chemical Information
-
CAS No. 313482-91-6
-
Appearance Solid
-
Masse moléculaire 366.39
-
Formule C19H14N2O4S
-
Color White to light yellow
-
SMILES
O=C(O)C1=CC=CC(NC(C2=CC=CC(NC(C3=CC=CS3)=O)=C2)=O)=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : ≥ 200 mg/mL (545.87 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Yangshun Tang, et al. Structure-based discovery of CZL80, a caspase-1 inhibitor with therapeutic potential for febrile seizures and later enhanced epileptogenic susceptibility. Br J Pharmacol. 2020 Aug;177(15):3519-3534. [Content Brief]
[2]. Ling Pan, et al. Novel Caspase-1 inhibitor CZL80 improves neurological function in mice after progressive ischemic stroke within a long therapeutic time-window. Acta Pharmacol Sin. 2022 Nov;43(11):2817-2827. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7293 mL | 13.6467 mL | 27.2933 mL | 68.2333 mL |
| 5 mM | 0.5459 mL | 2.7293 mL | 5.4587 mL | 13.6467 mL | |
| 10 mM | 0.2729 mL | 1.3647 mL | 2.7293 mL | 6.8233 mL | |
| 15 mM | 0.1820 mL | 0.9098 mL | 1.8196 mL | 4.5489 mL | |
| 20 mM | 0.1365 mL | 0.6823 mL | 1.3647 mL | 3.4117 mL | |
| 25 mM | 0.1092 mL | 0.5459 mL | 1.0917 mL | 2.7293 mL | |
| 30 mM | 0.0910 mL | 0.4549 mL | 0.9098 mL | 2.2744 mL | |
| 40 mM | 0.0682 mL | 0.3412 mL | 0.6823 mL | 1.7058 mL | |
| 50 mM | 0.0546 mL | 0.2729 mL | 0.5459 mL | 1.3647 mL | |
| 60 mM | 0.0455 mL | 0.2274 mL | 0.4549 mL | 1.1372 mL | |
| 80 mM | 0.0341 mL | 0.1706 mL | 0.3412 mL | 0.8529 mL | |
| 100 mM | 0.0273 mL | 0.1365 mL | 0.2729 mL | 0.6823 mL |
CZL80 Related Classifications
HY-131204 Related Classifications
Powered by Bioz